ATE147732T1 - Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten - Google Patents

Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten

Info

Publication number
ATE147732T1
ATE147732T1 AT90200499T AT90200499T ATE147732T1 AT E147732 T1 ATE147732 T1 AT E147732T1 AT 90200499 T AT90200499 T AT 90200499T AT 90200499 T AT90200499 T AT 90200499T AT E147732 T1 ATE147732 T1 AT E147732T1
Authority
AT
Austria
Prior art keywords
neurodegenerative diseases
tetrahydroquinoline derivatives
derivatives usable
usable
tetrahydroquinoline
Prior art date
Application number
AT90200499T
Other languages
English (en)
Inventor
Raymond Dr Baker
William R Dr Carling
Paul D Dr Leeson
Julian D Smith
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898905334A external-priority patent/GB8905334D0/en
Priority claimed from GB898926431A external-priority patent/GB8926431D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE147732T1 publication Critical patent/ATE147732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Other Liquid Machine Or Engine Such As Wave Power Use (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT90200499T 1989-03-08 1990-03-02 Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten ATE147732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898905334A GB8905334D0 (en) 1989-03-08 1989-03-08 Therapeutic agents
GB898926431A GB8926431D0 (en) 1989-11-22 1989-11-22 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE147732T1 true ATE147732T1 (de) 1997-02-15

Family

ID=26295073

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90200499T ATE147732T1 (de) 1989-03-08 1990-03-02 Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten

Country Status (11)

Country Link
EP (1) EP0386839B1 (de)
JP (1) JPH0334969A (de)
KR (1) KR900014321A (de)
AT (1) ATE147732T1 (de)
AU (1) AU5114490A (de)
CA (1) CA2011686A1 (de)
DE (1) DE69029668T2 (de)
FI (1) FI901148A0 (de)
IL (1) IL93610A0 (de)
NO (1) NO901082L (de)
PT (1) PT93362A (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268378A (en) * 1990-05-31 1993-12-07 Merck Sharp & Dohme, Limited Dioxo-tetrahydroquinoline derivatives
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
EP0573562B1 (de) * 1991-02-27 1996-04-24 Merrell Pharmaceuticals Inc. Dihydrochinolin NMDA Antagonisten
US5606063A (en) * 1991-02-27 1997-02-25 Merrell Pharmaceuticals Inc. NMDA antagonists
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
FR2683818B1 (fr) * 1991-11-14 1993-12-31 Adir Cie Nouveaux derives de 3-sulfonylamino-2-(1h)-quinoleinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9125515D0 (en) * 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
CA2232509A1 (en) * 1995-09-29 1997-04-10 Glaxo Wellcome Spa Tetrahydroquinolines as nmda antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
DE19705133A1 (de) * 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
EP1607389A1 (de) * 1999-09-10 2005-12-21 Pfizer Products Inc. 4-geschützte-amino-2-substituierte-1,2,3,4-Tetrahydrochinolin-Derivate zur Verwendung als Zwischenprodukte für CETP-Inhibitoren
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
CA2416454A1 (en) * 2000-12-07 2003-01-14 Japan Science And Technology Corporation Intermediates for synthesis of vinblastine and its congeners, and a method for synthesis of the intermediates
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ１（ｖｒ１）受容体を阻害するクロマニル尿素化合物およびその使用
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
EP3427729A1 (de) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH23848A (en) * 1985-05-24 1989-11-23 Ciba Geigy Ag Certain phosphonic acids and derivatives
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
EP0386839A3 (de) 1991-10-23
DE69029668T2 (de) 1997-08-07
JPH0334969A (ja) 1991-02-14
NO901082D0 (no) 1990-03-07
CA2011686A1 (en) 1990-09-08
IL93610A0 (en) 1990-12-23
EP0386839B1 (de) 1997-01-15
FI901148A0 (fi) 1990-03-07
PT93362A (pt) 1990-11-07
DE69029668D1 (de) 1997-02-27
KR900014321A (ko) 1990-10-23
EP0386839A2 (de) 1990-09-12
AU5114490A (en) 1990-09-13
NO901082L (no) 1990-09-10

Similar Documents

Publication Publication Date Title
ATE147732T1 (de) Tetrahydroquinolin-derivate, verwendbar bei neurodegenerativen krankheiten
DE3850676D1 (de) Hypotensive okulare Mittel.
ES2106825T3 (es) Derivados de piperidina.
NL300161I2 (nl) Carbostyrilderivaten.
NO894086D0 (no) Fremgangsmaate for fremstilling av piperidinylbenzimidazoler.
DE69014393D1 (de) Heterocyclische N-Oxid-Derivate substituierter Benzo[5,6]cycloheptapyridine, Zusammensetzungen und Methoden der Verwendung.
CS410991A3 (en) 2-substituted, 5-substituted 1,3-oxathiolate derivatives
DE69201302D1 (de) Therapeutische zusammenstellungen auf der basis von 1,2-dithiole-3-thionderivaten.
DE68923913D1 (de) Neplanocinderivate.
NO901391L (no) Fremgangsmaate for fremstilling av et 1,8-naftyridin-derivat.
DE68920913D1 (de) Serotonin-Antagonisten.
NO883070D0 (no) 4-aminosubstituerte 1,2-dihydroksynaftalin-derivater.
NO901631L (no) Fremgangsmaate for fremstilling av 2-substituerte n,n'-ditrimetoksybenzoyl-piperaziner.
ATE78023T1 (de) Leukotrienantagonisten.
IT1230768B (it) Derivati del 3,4 deidro piperidin 5 one ad attivita' erbicida.
NO910564L (no) Fremgangsmaate for fremstilling av azaspiro(4,5)decan-7,9-dionderivater.
MX9101899A (es) Indolizino(1,2-b)quinolinonas substituidas
MX9203773A (es) Derivados de quinolina como antagonistas de leucotrieno d4.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties